rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2025-37-45rsp-3697Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESГалектины, антитела к ним и галектин-3-связывающий белок при системной красной волчанкеGalectins, antibodies to them and galectin-3 binding protein in systemic lupus erythematosushttps://orcid.org/0000-0003-1147-5936КондратьеваЛ. В.KondratyevaL. V.

Кондратьева Любовь Валерьевна.

115522, Москва, Каширское шоссе, 34а

Liubov V. Kondratyeva.

115522, Moscow, Kashirskoye Highway, 34A

kondratyeva.liubov@yandex.ruhttps://orcid.org/0000-0001-5793-4689ПопковаТ. В.PopkovaT. V.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2025020320256313745Copyright © Кондратьева Л.В., Попкова Т.В., Насонов Е.Л., 20252025Кондратьева Л.В., Попкова Т.В., Насонов Е.Л.Kondratyeva L.V., Popkova T.V., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3697

При системной красной волчанке (СКВ) изучение галектинов связано с поиском новых биомаркеров активности, клинических проявлений, исходов заболевания. В представленном обзоре литературы обобщены сведения по наиболее хорошо известным галектинам-1, -3, -9, а также по антителам к галектинам и галектин-3-связывающему белку, полученные при культуральных исследованиях, на моделях волчанки у животных и у пациентов с СКВ.

The study of galectins is provoked by the search for new biomarkers of activity, clinical manifestations, and disease outcomes of systemic lupus erythematosus (SLE). The presented literature review summarizes the data on the most well-known galectins-1, -3, -9, as well as antibodies to galectins and galectin-3-binding protein, obtained in culture studies, in animal models of lupus and in patients with SLE.

системная красная волчанкабиомаркерыгалектин-1галектин-3галектин-9антитела к галектину-3галектин-3-связывающий белокsystemic lupus erythematosusbiomarkersgalectin-1galectin-3galectin-9antibodies to galectin-3galectin-3-binding proteinСтатья подготовлена в рамках научно-исследовательской работы ФГБНУ НИИР им. В.А. Насоновой (№ государственного задания PK 122040400024-7).ReferencesНасонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-412Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. doi: 10.1056/NEJMra1100359Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-2121. doi: 10.1056/NEJMra1100359Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39Capecchi R, Puxeddu I, Pratesi F, Migliorini P. New biomarkers in SLE: From bench to bedside. Rheumatology (Oxford). 2020;59(Suppl5):v12-v18. doi: 10.1093/rheumatology/keaa484Capecchi R, Puxeddu I, Pratesi F, Migliorini P. New biomarkers in SLE: From bench to bedside. Rheumatology (Oxford). 2020;59(Suppl5):v12-v18. doi: 10.1093/rheumatology/keaa484Johannes L, Jacob R, Leffler H. Galectins at a glance. J Cell Sci. 2018;131(9):jcs208884. doi: 10.1242/jcs.208884Johannes L, Jacob R, Leffler H. Galectins at a glance. J Cell Sci. 2018;131(9):jcs208884. doi: 10.1242/jcs.208884Mariño KV, Cagnoni AJ, Croci DO, Rabinovich GA. Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat Rev Drug Discov. 2023;22(4):295-316. doi: 10.1038/s41573-023-00636-2Mariño KV, Cagnoni AJ, Croci DO, Rabinovich GA. Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat Rev Drug Discov. 2023;22(4):295-316. doi: 10.1038/s41573-023-00636-2Liu FT, Stowell SR. The role of galectins in immunity and infection. Nat Rev Immunol. 2023;23(8):479-494. doi: 10.1038/s41577-022-00829-7Liu FT, Stowell SR. The role of galectins in immunity and infection. Nat Rev Immunol. 2023;23(8):479-494. doi: 10.1038/s41577-022-00829-7Giovannone N, Smith LK, Treanor B, Dimitroff CJ. Galectin-glycan interactions as regulators of B cell immunity. Front Immunol. 2018;9:2839. doi: 10.3389/fimmu.2018.02839Giovannone N, Smith LK, Treanor B, Dimitroff CJ. Galectin-glycan interactions as regulators of B cell immunity. Front Immunol. 2018;9:2839. doi: 10.3389/fimmu.2018.02839Thiemann S, Baum LG. Galectins and immune responses – Just how do they do those things they do? Annu Rev Immunol. 2016;34:243-264. doi: 10.1146/annurev-immunol-041015-055402Thiemann S, Baum LG. Galectins and immune responses – Just how do they do those things they do? Annu Rev Immunol. 2016;34:243-264. doi: 10.1146/annurev-immunol-041015-055402Montiel JL, Monsiváis-Urenda A, Figueroa-Vega N, Moctezuma JF, Burgos-Vargas R, González-Amaro R, et al. Anti-CD43 and anti-galectin-1 autoantibodies in patients with systemic lupus erythematosus. Scand J Rheumatol. 2010;39(1):50-57. doi: 10.3109/03009740903013213Montiel JL, Monsiváis-Urenda A, Figueroa-Vega N, Moctezuma JF, Burgos-Vargas R, González-Amaro R, et al. Anti-CD43 and anti-galectin-1 autoantibodies in patients with systemic lupus erythematosus. Scand J Rheumatol. 2010;39(1):50-57. doi: 10.3109/03009740903013213Kang EH, Moon KC, Lee EY, Lee YJ, Lee EB, Ahn C, et al. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus. 2009;18(1):22-28. doi: 10.1177/0961203308094361Kang EH, Moon KC, Lee EY, Lee YJ, Lee EB, Ahn C, et al. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus. 2009;18(1):22-28. doi: 10.1177/0961203308094361Gruszewska E, Cylwik B, Gińdzieńska-Sieśkiewicz E, Kowal-Bielecka O, Mroczko B, Chrostek L. Diagnostic power of galectin-3 in rheumatic diseases. J Clin Med. 2020;9(10):3312. doi: 10.3390/jcm9103312Gruszewska E, Cylwik B, Gińdzieńska-Sieśkiewicz E, Kowal-Bielecka O, Mroczko B, Chrostek L. Diagnostic power of galectin-3 in rheumatic diseases. J Clin Med. 2020;9(10):3312. doi: 10.3390/jcm9103312Koca SS, Akbas F, Ozgen M, Yolbas S, Ilhan N, Gundogdu B, et al. Serum galectin-3 level in systemic sclerosis. Clin Rheumatol. 2014;33(2):215-220. doi: 10.1007/s10067-013-2346-8Koca SS, Akbas F, Ozgen M, Yolbas S, Ilhan N, Gundogdu B, et al. Serum galectin-3 level in systemic sclerosis. Clin Rheumatol. 2014;33(2):215-220. doi: 10.1007/s10067-013-2346-8Shi Z, Meng Z, Han Y, Cao C, Tan G, Wang L. The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients. Lupus. 2018;27(4):621-627. doi: 10.1177/0961203317736144Shi Z, Meng Z, Han Y, Cao C, Tan G, Wang L. The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients. Lupus. 2018;27(4):621-627. doi: 10.1177/0961203317736144Kalinska-Bienias A, Kowalczyk E, Bienias P, Gala K, Jagielski P, Kowalewski C. Serum galectin-3 and galectin-3 binding protein levels in systemic lupus erythematosus and cutaneous lupus erythematosus. Postepy Dermatol Alergol. 2021;38(2):274-280. doi: 10.5114/ada.2020.92320Kalinska-Bienias A, Kowalczyk E, Bienias P, Gala K, Jagielski P, Kowalewski C. Serum galectin-3 and galectin-3 binding protein levels in systemic lupus erythematosus and cutaneous lupus erythematosus. Postepy Dermatol Alergol. 2021;38(2):274-280. doi: 10.5114/ada.2020.92320Koletsos N, Lazaridis A, Triantafyllou A, Anyfanti P, Lamprou S, Stoimeni A, et al. Accumulation of microvascular target organ damage in systemic lupus erythematosus patients is associated with increased cardiovascular risk. J Clin Med. 2024;13(7):2140. doi: 10.3390/jcm13072140Koletsos N, Lazaridis A, Triantafyllou A, Anyfanti P, Lamprou S, Stoimeni A, et al. Accumulation of microvascular target organ damage in systemic lupus erythematosus patients is associated with increased cardiovascular risk. J Clin Med. 2024;13(7):2140. doi: 10.3390/jcm13072140Jiao Q, Qian Q, Zhao Z, Fang F, Hu X, An J, et al. Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) and TIM-3 ligands in peripheral blood from patients with systemic lupus erythematosus. Arch Dermatol Res. 2016;308(8):553-61. doi: 10.1007/s00403-016-1665-4Jiao Q, Qian Q, Zhao Z, Fang F, Hu X, An J, et al. Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) and TIM-3 ligands in peripheral blood from patients with systemic lupus erythematosus. Arch Dermatol Res. 2016;308(8):553-61. doi: 10.1007/s00403-016-1665-4van den Hoogen LL, van Roon JAG, Mertens JS, Wienke J, Lopes AP, de Jager W, et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2018;77(12):1810-1814. doi: 10.1136/annrheumdis-2018-213497van den Hoogen LL, van Roon JAG, Mertens JS, Wienke J, Lopes AP, de Jager W, et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2018;77(12):1810-1814. doi: 10.1136/annrheumdis-2018-213497Enocsson H, Wetterö J, Eloranta ML, Gullstrand B, Svanberg C, Larsson M, et al. Comparison of surrogate markers of the type I interferon response and their ability to mirror disease activity in systemic lupus erythematosus. Front Immunol. 2021;12:688753. doi: 10.3389/fimmu.2021.688753Enocsson H, Wetterö J, Eloranta ML, Gullstrand B, Svanberg C, Larsson M, et al. Comparison of surrogate markers of the type I interferon response and their ability to mirror disease activity in systemic lupus erythematosus. Front Immunol. 2021;12:688753. doi: 10.3389/fimmu.2021.688753Matsuoka N, Fujita Y, Temmoku J, Furuya MY, Asano T, Sato S, et al. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus. PLoS One. 2020;15(1):e0227069. doi: 10.1371/journal.pone.0227069Matsuoka N, Fujita Y, Temmoku J, Furuya MY, Asano T, Sato S, et al. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus. PLoS One. 2020;15(1):e0227069. doi: 10.1371/journal.pone.0227069Mehta P, Singh P, Aggarwal A. Serum and urinary galectin-9 and C-X-C motif chemokine ligand 10. Lupus. 2022;31(4):482-487. doi: 10.1177/09612033221082907Mehta P, Singh P, Aggarwal A. Serum and urinary galectin-9 and C-X-C motif chemokine ligand 10. Lupus. 2022;31(4):482-487. doi: 10.1177/09612033221082907Gensous N, Vagner D, Barnetche T, Duffau P, Lazaro E, Richez C, et al. CXCL-10 and tumor necrosis factor receptor type II as biomarkers of disease activity in systemic lupus erythematosus. Joint Bone Spine. 2022;89(3):105311. doi: 10.1016/j.jbspin.2021.105311Gensous N, Vagner D, Barnetche T, Duffau P, Lazaro E, Richez C, et al. CXCL-10 and tumor necrosis factor receptor type II as biomarkers of disease activity in systemic lupus erythematosus. Joint Bone Spine. 2022;89(3):105311. doi: 10.1016/j.jbspin.2021.105311Szabó E, Faragó A, Bodor G, Gémes N, Puskás LG, Kovács L, et al. Identification of immune subsets with distinct lectin binding signatures using multi-parameter flow cytometry: Correlations with disease activity in systemic lupus erythematosus. Front Immunol. 2024;15:1380481. doi: 10.3389/fimmu.2024.1380481Szabó E, Faragó A, Bodor G, Gémes N, Puskás LG, Kovács L, et al. Identification of immune subsets with distinct lectin binding signatures using multi-parameter flow cytometry: Correlations with disease activity in systemic lupus erythematosus. Front Immunol. 2024;15:1380481. doi: 10.3389/fimmu.2024.1380481Szabó E, Hornung Á, Monostori É, Bocskai M, Czibula Á, Kovács L. Altered cell surface N-glycosylation of resting and activated T cells in systemic lupus erythematosus. Int J Mol Sci. 2019;20(18):4455. doi: 10.3390/ijms20184455Szabó E, Hornung Á, Monostori É, Bocskai M, Czibula Á, Kovács L. Altered cell surface N-glycosylation of resting and activated T cells in systemic lupus erythematosus. Int J Mol Sci. 2019;20(18):4455. doi: 10.3390/ijms20184455Jiang X, Xiao X, Li H, Gong Y, Wang M, Yang H, et al. Oxidized galectin-1 in SLE fails to bind the inhibitory receptor VSTM1 and increases reactive oxygen species levels in neutrophils. Cell Mol Immunol. 2023;20(11):1339-1351. doi: 10.1038/s41423-023-01084-zJiang X, Xiao X, Li H, Gong Y, Wang M, Yang H, et al. Oxidized galectin-1 in SLE fails to bind the inhibitory receptor VSTM1 and increases reactive oxygen species levels in neutrophils. Cell Mol Immunol. 2023;20(11):1339-1351. doi: 10.1038/s41423-023-01084-zChen SY, Wang CT, Chen CY, Kuo PY, Wang CR, Shiau AL, et al. Galectin-3 mediates NETosis and acts as an autoantigen in systemic lupus erythematosus-associated diffuse alveolar haemorrhage. Int J Mol Sci. 2023;24(11):9493. doi: 10.3390/ijms24119493Chen SY, Wang CT, Chen CY, Kuo PY, Wang CR, Shiau AL, et al. Galectin-3 mediates NETosis and acts as an autoantigen in systemic lupus erythematosus-associated diffuse alveolar haemorrhage. Int J Mol Sci. 2023;24(11):9493. doi: 10.3390/ijms24119493Shi Z, Zhang YP, Hong D, Qiu X, Zheng L, Bian L, et al. Antigalectin-3 antibodies induce skin vascular inflammation via promoting local production of IL-1β in systemic lupus erythematosus. Int Immunopharmacol. 2022;112:109197. doi: 10.1016/j.intimp.2022.109197Shi Z, Zhang YP, Hong D, Qiu X, Zheng L, Bian L, et al. Antigalectin-3 antibodies induce skin vascular inflammation via promoting local production of IL-1β in systemic lupus erythematosus. Int Immunopharmacol. 2022;112:109197. doi: 10.1016/j.intimp.2022.109197Shi ZR, Tan GZ, Meng Z, Yu M, Li KW, Yin J, et al. Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(1):193-203. doi: 10.1002/art.38891Shi ZR, Tan GZ, Meng Z, Yu M, Li KW, Yin J, et al. Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(1):193-203. doi: 10.1002/art.38891Nielsen CT, Lood C, Ostergaard O, Iversen LV, Voss A, Bengtsson A, et al. Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med. 2014;1(1):e000026. doi: 10.1136/lupus-2014-000026Nielsen CT, Lood C, Ostergaard O, Iversen LV, Voss A, Bengtsson A, et al. Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med. 2014;1(1):e000026. doi: 10.1136/lupus-2014-000026Østergaard O, Nielsen CT, Iversen LV, Tanassi JT, Knudsen S, Jacobsen S, et al. Unique protein signature of circulating microparticles in systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2680-2690. doi: 10.1002/art.38065Østergaard O, Nielsen CT, Iversen LV, Tanassi JT, Knudsen S, Jacobsen S, et al. Unique protein signature of circulating microparticles in systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2680-2690. doi: 10.1002/art.38065Ullal AJ, Reich CF 3rd, Clowse M, Criscione-Schreiber LG, Tochacek M, Monestier M, et al. Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J Autoimmun. 2011;36(3-4):173-180. doi: 10.1016/j.jaut.2011.02.001Ullal AJ, Reich CF 3rd, Clowse M, Criscione-Schreiber LG, Tochacek M, Monestier M, et al. Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J Autoimmun. 2011;36(3-4):173-180. doi: 10.1016/j.jaut.2011.02.001Liu SD, Lee S, La Cava A, Motran CC, Hahn BH, Miceli MC. Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease. Lupus. 2011;20(5):473-484. doi: 10.1177/0961203310388444Liu SD, Lee S, La Cava A, Motran CC, Hahn BH, Miceli MC. Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease. Lupus. 2011;20(5):473-484. doi: 10.1177/0961203310388444Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke DS, et al. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight. 2024;9(2):e172569. doi: 10.1172/jci.insight.172569Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke DS, et al. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight. 2024;9(2):e172569. doi: 10.1172/jci.insight.172569Насонов ЕЛ, Авдеева АС, Решетняк ТМ, Алексанкин АП, Рубцов ЮП. Роль нетоза в патогенезе иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2023;61(5):513-530. doi: 10.47360/1995-4484-2023-513-530Nasonov EL, Avdeeva AS, Reshetnyak TM, Aleksankin AP, Rubtsov YuP. The role of NETosis in the pathogenesis of immunoinflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(5):513-530 (In Russ.). doi: 10.47360/1995-4484-2023-513-530Beccaria CG, Amezcua Vesely MC, Fiocca Vernengo F, Gehrau RC, Ramello MC, Tosello Boari J, et al. Galectin-3 deficiency drives lupus-like disease by promoting spontaneous germinal centers formation via IFN-γ. Nat Commun. 2018;9(1):1628. doi: 10.1038/s41467-018-04063-5Beccaria CG, Amezcua Vesely MC, Fiocca Vernengo F, Gehrau RC, Ramello MC, Tosello Boari J, et al. Galectin-3 deficiency drives lupus-like disease by promoting spontaneous germinal centers formation via IFN-γ. Nat Commun. 2018;9(1):1628. doi: 10.1038/s41467-018-04063-5Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;55(4):452-461. doi: 10.14412/1995-4484-2019-452-461Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.). doi: 10.14412/1995-4484-2019-452-461Kuca-Warnawin E, Skalska U, Janicka I, Musiałowicz U, Bonek K, Głuszko P, et al. The phenotype and secretory activity of adipose-derived mesenchymal stem cells (ASCs) of patients with rheumatic diseases. Cells. 2019;8(12):1659. doi: 10.3390/cells8121659Kuca-Warnawin E, Skalska U, Janicka I, Musiałowicz U, Bonek K, Głuszko P, et al. The phenotype and secretory activity of adipose-derived mesenchymal stem cells (ASCs) of patients with rheumatic diseases. Cells. 2019;8(12):1659. doi: 10.3390/cells8121659Zhao CN, Mao YM, Liu LN, Wu Q, Dan YL, Pan HF. Plasma galectin-3 levels do not differ in systemic lupus erythematosus patients. Int J Rheum Dis. 2019;22(10):1820-1824. doi: 10.1111/1756-185X.13677Zhao CN, Mao YM, Liu LN, Wu Q, Dan YL, Pan HF. Plasma galectin-3 levels do not differ in systemic lupus erythematosus patients. Int J Rheum Dis. 2019;22(10):1820-1824. doi: 10.1111/1756-185X.13677Faustini F, Idborg H, Fuzzi E, Larsson A, Lie WR, Pötzsch S, et al. Urine galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus. Lupus. 2023;32(2):252-262. doi: 10.1177/09612033221145534Faustini F, Idborg H, Fuzzi E, Larsson A, Lie WR, Pötzsch S, et al. Urine galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus. Lupus. 2023;32(2):252-262. doi: 10.1177/09612033221145534Guo Y, Li L, Hu S. Circulating galectin-3 levels and diabetic nephropathy: A systematic review and meta-analysis. BMC Nephrol. 2023;24(1):163. doi: 10.1186/s12882-023-03226-xGuo Y, Li L, Hu S. Circulating galectin-3 levels and diabetic nephropathy: A systematic review and meta-analysis. BMC Nephrol. 2023;24(1):163. doi: 10.1186/s12882-023-03226-xKikuchi Y, Kobayashi S, Hemmi N, Ikee R, Hyodo N, Saigusa T, et al. Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant. 2004;19(3):602-607. doi: 10.1093/ndt/gfg603Kikuchi Y, Kobayashi S, Hemmi N, Ikee R, Hyodo N, Saigusa T, et al. Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant. 2004;19(3):602-607. doi: 10.1093/ndt/gfg603Li LC, Li J, Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014;351(2):336-343. doi: 10.1124/jpet.114.218370Li LC, Li J, Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014;351(2):336-343. doi: 10.1124/jpet.114.218370Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006;103(13):5060-5065. doi: 10.1073/pnas.0511167103Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006;103(13):5060-5065. doi: 10.1073/pnas.0511167103Jia Q, Yang Y, Yao S, Chen X, Hu Z. Emerging roles of galectin-3 in pulmonary diseases. Lung. 2024;202(4):385-403. doi: 10.1007/s00408-024-00709-yJia Q, Yang Y, Yao S, Chen X, Hu Z. Emerging roles of galectin-3 in pulmonary diseases. Lung. 2024;202(4):385-403. doi: 10.1007/s00408-024-00709-yГямджян КА, Драпкина ОМ, Максимов МЛ. Галектин-3: клиническая и прогностическая ценность определения у пациентов с хронической сердечной недостаточностью. Журнал Cердечная недостаточность. 2014;82(1):51-55.Gyamdzhyan KA, Drapkina OM, Maksimov ML. Galectin-3: Clinical and prognostic significance of determination in patients with chronic heart failure. Heart Failure Journal. 2014;82(1):51-55 (In Russ.).Анкудинов АС, Калягин АН. Применение галектина-3 в оценке тяжести хронической сердечной недостаточности, ассоциированной с ревматоидным артритом. Результаты анализа. Доктор.Ру. 2021;20(11):12-16. doi: 10.31550/1727-2378-2021-20-11-12-16Ankudinov AS, Kalyagin AN. Use of galectin-3 in the assessment of the severity of chronic heart failure associated with rheumatoid arthritis. Results of the analysis. Doctor.Ru. 2021;20(11):12-16 (In Russ.). doi: 10.31550/1727-2378-2021-20-11-12-16Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Müller I. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. Eur J Immunol. 2013;43(10):2741-2749. doi: 10.1002/eji.201343335Gieseke F, Kruchen A, Tzaribachev N, Bentzien F, Dominici M, Müller I. Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. Eur J Immunol. 2013;43(10):2741-2749. doi: 10.1002/eji.201343335Zeggar S, Watanabe KS, Teshigawara S, Hiramatsu S, Katsuyama T, Katsuyama E, et al. Role of Lgals9 deficiency in attenuating nephritis and arthritis in BALB/c mice in a pristane-induced lupus model. Arthritis Rheumatol. 2018;70(7):1089-1101. doi: 10.1002/art.40467Zeggar S, Watanabe KS, Teshigawara S, Hiramatsu S, Katsuyama T, Katsuyama E, et al. Role of Lgals9 deficiency in attenuating nephritis and arthritis in BALB/c mice in a pristane-induced lupus model. Arthritis Rheumatol. 2018;70(7):1089-1101. doi: 10.1002/art.40467Panda SK, Facchinetti V, Voynova E, Hanabuchi S, Karnell JL, Hanna RN, et al. Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models. J Clin Invest. 2018;128(5):1873-1887. doi: 10.1172/JCI97333Panda SK, Facchinetti V, Voynova E, Hanabuchi S, Karnell JL, Hanna RN, et al. Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models. J Clin Invest. 2018;128(5):1873-1887. doi: 10.1172/JCI97333Moritoki M, Kadowaki T, Niki T, Nakano D, Soma G, Mori H, et al. Galectin-9 ameliorates clinical severity of MRL/lpr lupusprone mice by inducing plasma cell apoptosis independently of Tim-3. PLoS One. 2013;8(4):e60807. doi: 10.1371/journal.pone.0060807Moritoki M, Kadowaki T, Niki T, Nakano D, Soma G, Mori H, et al. Galectin-9 ameliorates clinical severity of MRL/lpr lupusprone mice by inducing plasma cell apoptosis independently of Tim-3. PLoS One. 2013;8(4):e60807. doi: 10.1371/journal.pone.0060807Yuksel K, Sag E, Demir S, Özdel S, Kaya UA, Atalay E, et al. Plasma checkpoint protein levels and galectin-9 in juvenile systemic lupus erythematosus. Lupus. 2021;30(6):998-1004. doi: 10.1177/09612033211002275Yuksel K, Sag E, Demir S, Özdel S, Kaya UA, Atalay E, et al. Plasma checkpoint protein levels and galectin-9 in juvenile systemic lupus erythematosus. Lupus. 2021;30(6):998-1004. doi: 10.1177/09612033211002275van den Hoogen LL, van der Heijden EHM, Hillen MR, Mertens JS, Fritsch-Stork RDE, Radstake TRDJ, et al. Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to: ’Biomarkers: to be or not to be’ by Yavuz and Rönnblom. Ann Rheum Dis. 2020;79(1):e9. doi: 10.1136/annrheumdis-2018-214651van den Hoogen LL, van der Heijden EHM, Hillen MR, Mertens JS, Fritsch-Stork RDE, Radstake TRDJ, et al. Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to: ’Biomarkers: to be or not to be’ by Yavuz and Rönnblom. Ann Rheum Dis. 2020;79(1):e9. doi: 10.1136/annrheumdis-2018-214651Wang Y, Song L, Sun J, Sui Y, Li D, Li G, et al. Expression of galectin-9 and correlation with disease activity and vascular endothelial growth factor in rheumatoid arthritis. Clin Exp Rheumatol. 2020;38(4):654-661.Wang Y, Song L, Sun J, Sui Y, Li D, Li G, et al. Expression of galectin-9 and correlation with disease activity and vascular endothelial growth factor in rheumatoid arthritis. Clin Exp Rheumatol. 2020;38(4):654-661.Fujita Y, Asano T, Matsuoka N, Temmoku J, Sato S, Matsumoto H, et al. Differential regulation and correlation between galectin-9 and anti-CCP antibody (ACPA) in rheumatoid arthritis patients. Arthritis Res Ther. 2020;22(1):80. doi: 10.1186/s13075-020-02158-3Fujita Y, Asano T, Matsuoka N, Temmoku J, Sato S, Matsumoto H, et al. Differential regulation and correlation between galectin-9 and anti-CCP antibody (ACPA) in rheumatoid arthritis patients. Arthritis Res Ther. 2020;22(1):80. doi: 10.1186/s13075-020-02158-3Wienke J, Bellutti Enders F, Lim J, Mertens JS, van den Hoogen LL, Wijngaarde CA, et al. Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: A longitudinal cohort study and multicohort validation. Arthritis Rheumatol. 2019;71(8):1377-1390. doi: 10.1002/art.40881Wienke J, Bellutti Enders F, Lim J, Mertens JS, van den Hoogen LL, Wijngaarde CA, et al. Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: A longitudinal cohort study and multicohort validation. Arthritis Rheumatol. 2019;71(8):1377-1390. doi: 10.1002/art.40881Matsuoka N, Kozuru H, Koga T, Abiru S, Yamasaki K, Komori A, et al. Galectin-9 in autoimmune hepatitis: Correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis. Medicine (Baltimore). 2019;98(35):e16924. doi: 10.1097/MD.0000000000016924Matsuoka N, Kozuru H, Koga T, Abiru S, Yamasaki K, Komori A, et al. Galectin-9 in autoimmune hepatitis: Correlation between serum levels of galectin-9 and M2BPGi in patients with autoimmune hepatitis. Medicine (Baltimore). 2019;98(35):e16924. doi: 10.1097/MD.0000000000016924Sarter K, Janko C, André S, Muñoz LE, Schorn C, Winkler S, Rech J, et al. Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. Glycobiology. 2013;23(1):12-22. doi: 10.1093/glycob/cws120Sarter K, Janko C, André S, Muñoz LE, Schorn C, Winkler S, Rech J, et al. Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. Glycobiology. 2013;23(1):12-22. doi: 10.1093/glycob/cws120Janko C, André S, Munoz LE, Briand JP, Schorn C, Winkler S, et al. Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. Lupus. 2012;21(7):781-783. doi: 10.1177/0961203312443422Janko C, André S, Munoz LE, Briand JP, Schorn C, Winkler S, et al. Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. Lupus. 2012;21(7):781-783. doi: 10.1177/0961203312443422Lim Y, Lee DY, Lee S, Park SY, Kim J, Cho B, et al. Identification of autoantibodies associated with systemic lupus erythematosus. Biochem Biophys Res Commun. 2002;295(1):119-124. doi: 10.1016/s0006-291x(02)00637-xLim Y, Lee DY, Lee S, Park SY, Kim J, Cho B, et al. Identification of autoantibodies associated with systemic lupus erythematosus. Biochem Biophys Res Commun. 2002;295(1):119-124. doi: 10.1016/s0006-291x(02)00637-xRasmussen NS, Nielsen CT, Houen G, Jacobsen S. Humoral markers of active Epstein – Barr virus infection associate with antiextractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus. Lupus. 2016;25(14):1567-1576. doi: 10.1177/0961203316644334Rasmussen NS, Nielsen CT, Houen G, Jacobsen S. Humoral markers of active Epstein – Barr virus infection associate with antiextractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus. Lupus. 2016;25(14):1567-1576. doi: 10.1177/0961203316644334Rasmussen NS, Draborg AH, Houen G, Nielsen CT. Human herpesvirus infections and circulating microvesicles expressing galectin-3 binding protein in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2022;40(1):158-161. doi: 10.55563/clinexprheumatol/s364rtRasmussen NS, Draborg AH, Houen G, Nielsen CT. Human herpesvirus infections and circulating microvesicles expressing galectin-3 binding protein in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2022;40(1):158-161. doi: 10.55563/clinexprheumatol/s364rtLoimaranta V, Hepojoki J, Laaksoaho O, Pulliainen AT. Galectin-3-binding protein: A multitask glycoprotein with innate immunity functions in viral and bacterial infections. J Leukoc Biol. 2018; 104(4):777-786. doi: 10.1002/JLB.3VMR0118-036RLoimaranta V, Hepojoki J, Laaksoaho O, Pulliainen AT. Galectin-3-binding protein: A multitask glycoprotein with innate immunity functions in viral and bacterial infections. J Leukoc Biol. 2018; 104(4):777-786. doi: 10.1002/JLB.3VMR0118-036RCapone E, Iacobelli S, Sala G. Role of galectin 3 binding protein in cancer progression: A potential novel therapeutic target. J Transl Med. 2021;19(1):405. doi: 10.1186/s12967-021-03085-wCapone E, Iacobelli S, Sala G. Role of galectin 3 binding protein in cancer progression: A potential novel therapeutic target. J Transl Med. 2021;19(1):405. doi: 10.1186/s12967-021-03085-wKeinänen O, Sarrett SM, Delaney S, Rodriguez C, Dayts EJ, Capone E, et al. Visualizing galectin-3 binding protein expression with ImmunoPET. Mol Pharm. 2023;20(6):3241-3248. doi: 10.1021/acs.molpharmaceut.3c00241Keinänen O, Sarrett SM, Delaney S, Rodriguez C, Dayts EJ, Capone E, et al. Visualizing galectin-3 binding protein expression with ImmunoPET. Mol Pharm. 2023;20(6):3241-3248. doi: 10.1021/acs.molpharmaceut.3c00241Lee YJ, Kang SW, Song JK, Park JJ, Bae YD, Lee EY, et al. Serum galectin-3 and galectin-3 binding protein levels in Behçet’s disease and their association with disease activity. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S41-S45.Lee YJ, Kang SW, Song JK, Park JJ, Bae YD, Lee EY, et al. Serum galectin-3 and galectin-3 binding protein levels in Behçet’s disease and their association with disease activity. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S41-S45.Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2788-2795. doi: 10.1002/art.11287Ohshima S, Kuchen S, Seemayer CA, Kyburz D, Hirt A, Klinzing S, et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2788-2795. doi: 10.1002/art.11287Ahn SS, Park Y, Lee DD, Bothwell ALM, Jung SM, Song JJ, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein can reflect systemic lupus erythematosus activity. Lupus. 2018;27(5):771-779. doi: 10.1177/0961203317747719Ahn SS, Park Y, Lee DD, Bothwell ALM, Jung SM, Song JJ, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein can reflect systemic lupus erythematosus activity. Lupus. 2018;27(5):771-779. doi: 10.1177/0961203317747719Peretz ASR, Rasmussen NS, Jacobsen S, Sjöwall C, Nielsen CT. Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus. Clin Exp Rheumatol. 2021;39(6):1360-1368. doi: 10.55563/clinexprheumatol/ol0vqjPeretz ASR, Rasmussen NS, Jacobsen S, Sjöwall C, Nielsen CT. Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus. Clin Exp Rheumatol. 2021;39(6):1360-1368. doi: 10.55563/clinexprheumatol/ol0vqjDeRoo EP, Wrobleski SK, Shea EM, Al-Khalil RK, Hawley AE, Henke PK, et al. The role of galectin-3 and galectin-3-binding protein in venous thrombosis. Blood. 2015;125(11):1813-1821. doi: 10.1182/blood-2014-04-569939DeRoo EP, Wrobleski SK, Shea EM, Al-Khalil RK, Hawley AE, Henke PK, et al. The role of galectin-3 and galectin-3-binding protein in venous thrombosis. Blood. 2015;125(11):1813-1821. doi: 10.1182/blood-2014-04-569939Diaz JA, Hawley AE, Wrobleski SK, Shea E, DeRoo E, Al-Khalil R, et al. Galectin-3 binding protein and galectin-3: Novel factors promoting venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2013;1(1):102. doi: 10.1016/j.jvsv.2012.10.012Diaz JA, Hawley AE, Wrobleski SK, Shea E, DeRoo E, Al-Khalil R, et al. Galectin-3 binding protein and galectin-3: Novel factors promoting venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2013;1(1):102. doi: 10.1016/j.jvsv.2012.10.012Gleissner CA, Erbel C, Linden F, Domschke G, Akhavanpoor M, Doesch AO, et al. Galectin-3 binding protein plasma levels are associated with long-term mortality in coronary artery disease independent of plaque morphology. Atherosclerosis. 2016;251:94-100. doi: 10.1016/j.atherosclerosis.2016.06.002Gleissner CA, Erbel C, Linden F, Domschke G, Akhavanpoor M, Doesch AO, et al. Galectin-3 binding protein plasma levels are associated with long-term mortality in coronary artery disease independent of plaque morphology. Atherosclerosis. 2016;251:94-100. doi: 10.1016/j.atherosclerosis.2016.06.002Gleissner CA, Erbel C, Linden F, Domschke G, Akhavanpoor M, Helmes CM, et al. Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: Insights from the LURIC study. Atherosclerosis. 2017;260:121-129. doi: 10.1016/j.atherosclerosis.2017.03.031Gleissner CA, Erbel C, Linden F, Domschke G, Akhavanpoor M, Helmes CM, et al. Galectin-3 binding protein, coronary artery disease and cardiovascular mortality: Insights from the LURIC study. Atherosclerosis. 2017;260:121-129. doi: 10.1016/j.atherosclerosis.2017.03.031Nielsen CT, Østergaard O, Rekvig OP, Sturfelt G, Jacobsen S, Heegaard NH. Galectin-3 binding protein links circulating microparticles with electron dense glomerular deposits in lupus nephritis. Lupus. 2015;24(11):1150-1160. doi: 10.1177/0961203315580146Nielsen CT, Østergaard O, Rekvig OP, Sturfelt G, Jacobsen S, Heegaard NH. Galectin-3 binding protein links circulating microparticles with electron dense glomerular deposits in lupus nephritis. Lupus. 2015;24(11):1150-1160. doi: 10.1177/0961203315580146Ding H, Shen Y, Lin C, Qin L, He S, Dai M, et al. Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis. Arthritis Res Ther. 2022;24(1):77. doi: 10.1186/s13075-022-02763-4Ding H, Shen Y, Lin C, Qin L, He S, Dai M, et al. Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis. Arthritis Res Ther. 2022;24(1):77. doi: 10.1186/s13075-022-02763-4

The authors declare that there are no conflicts of interest present.